Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, and Crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for breast cancer; and GB492, a stimulator of interferon genes combined with GB226, currently under Phase 1/2 clinical trial to treat solid tumours. Additionally, the company develops GB226, which is in Phase III clinical trial. It also works on GB261, in Phase I/II clinical trial for NHL, and GB263T, in Phase I/II clinical trial for NSCLC. Furthermore, it develops GB221, in Phase III clinical trial; GB223, in Phase I clinical trial; GB241, also in Phase III clinical trial; and GB251, which is in Phase I clinical trial. The company's product candidates in pre-clinical trials include GB262, GB264, GB266, GB267, and GB268 for cancer treatment. Genor Biopharma was formerly known as JHBP (CY) Holdings Limited and changed its name in June 2021. Founded in 2007, the company is headquartered in Shanghai, China.